

**Table SIII. Previously reported cases of localized injection-site toxic erythema of chemotherapy (TEC) (localized epidermal necrosis; EN) available in the literature**

Reference	Cases, n	Description	Involved cytostatic	Chemo-therapy cycle	Onset time	Location	Clinical appearance	Histopathology	Resolution/Other
Chan and Lin (S15).	1	Serpentine supraveneous pigmentation	Doxorubicin + cyclophosphamide + 5-FU	1	1 day	Left arm	EM	Hyperkeratotic epidermis, vacuolization of the basal layer, necrotic keratinocytes, and lymphocytic infiltrate (often perivascular)	Resolution in 4 months. Erythematous phase preceding hyperpigmentation.
Ghosh et al. (S12).	1	Docetaxel-induced supraveneous serpentine dermatitis	Docetaxel	1	1 day	Right arm	PSE	Basket-weave pattern of hyperkeratosis, spongiosis with lymphocytic and neutrophilic exocytosis, irregular acanthosis, focal basal cell degeneration, upper dermal band-like as well as perivascular lympho-mononuclear infiltrates, and papillary dermal oedema	Practically solved in 4 weeks with mometasone furoate cream tid.
Aydogan (S1)	1	Persistent serpentine supraveneous hyperpigmented eruption	Cisplatin + gemcitabine + Docetaxel	1	2 days	Right arm	PSE	Hyperkeratosis, vacuolization of the basal layer and necrotic keratinocytes	Resolution in 6 months
Rao and Balachandran (S2)	1	Persistent supraveneous eruption	Bortezomib + CHOP	1	8 hours	Right arm, Left arm	PSE	Interface dermatitis with isolated necrotic keratinocytes, oedema of the underlying papillary dermis, and a superficial perivascular inflammatory infiltrate	Third infusion with no lesions. Resolution in 5 months
Mataix et al. (S3)	1	Persistent supraveneous erythematous eruption	5-FU	1	4 days	Both arms	PSE	Vacuolar degeneration, necrotic keratinocytes.	Residual pigmentation
Vukelja et al. (S4)	1	Serpentine supraveneous pigmentation	5-FU + Oxaliplatin	1	1 day	Right arm	PSE	Interface dermatitis with vacuolization of the basal cells and necrotic keratinocytes.	Gradual vanishing in 3 months
Arias et al. (S8)	1	EM-like	Vinblastin	1	1 days	Forearm	EM	-	Scaliness in 1 week
Nigro and Hsu (S5)	1	Supraveneous serpentine scaling	Actinomycin D + Vincristine	1	7 days	Arm	PSE	Vacuolization. Lymphocytoclastic vasculitis	Persistent at 5 months
Chen et al. (S6)	2	Linear supraveneous papules	Bromodeoxyuridine	NR	2 days	Forearm	PSE	NR	Peeling in 1 week
Zimmerman et al. (S7)	3	Isolated erythrodysesthesia lesion	Docetaxel	1, 2, 3	NR	Forearm	FDE	NR	-
Fine and Breathnach (S8)	3	Local reactions	Paclitaxel	-	-	-	PSE	-	-
Hiral et al. (S9)	1	EM-like	Docetaxel	1	7 days	Forearm	EM	-	-
Dorr and Jones (S10).	4	Absent infiltration	Vindesine	NR	1 days	Both hands	FDE	-	Ulceration
Spencer (S11)	1	EM-like	Mitomycin + 5-FU	3	1 days	Both forearms	EM	Vacuolar degeneration, necrotic keratinocytes	Peeling in 2 weeks
Koehn and Balizet (S12)	1	Local cutaneous reaction	Dacarbazine	4	1 days	Forearm	EM	Basal vacuolar degeneration, necrotic keratinocytes	Peeling in 3 weeks
Misery et al. (S13)	1	Local EN	Vinorelbine	2	2 days	Forearm	EM	Basal vacuolar degeneration, necrotic keratinocytes	Residual pigmentation
Chu et al. (S10).	4	Located erythrodysesthesia	Docetaxel	1,2,3	7-14 days	Forearm - hand's dorsum	FDE (3) PSE (1)	-	Residual pigmentation. Scaliness in 6 weeks
Correia et al. (S14)	2	Located erythrodysesthesia	Docetaxel	NR	5-8 days	Forearm	FDE	Vacuolar degeneration, eczema	NR
Suvirya et al. (S15)	1	Persistent serpentine supraveneous hyperpigmented eruption	5-FU	1 (left forearm) 2 (right forearm)	2 days	Both forearms	PSE	Sparse superficial perivascular infiltrate predominantly of melanophages with a few lymphocytes. Slight flattening of rete ridges and the papillary dermis showed mild fibroplasia	Significant decrease in hyperpigmentation at the end of fourth month
Das et al. (S16)	1	Supraveneous serpentine dermatitis	Docetaxel	1	2 days	Lower limb	PSE	Basal layer degeneration, pigment incontinence, melanophages, focal band-like infiltrate as well as perivascular mononuclear infiltrate	NR

Table SIII. Contd.

Reference	Cases, n	Description	Involved cytostatic	Chemotherapy cycle	Onset time	Location	Clinical appearance	Histopathology	Resolution/Other
Akyurek et al. (S17)	1	Serpentine supravenuous hyperpigmentation	Carboplatin + Vinorelbine	1	14 days	Left forearm	PSE	Loss of superficial epidermis and dermal lympho-cytic infiltration, focal oedema, and scant extravasated erythrocytes	Amelioration of erythematous and bullous lesions within a few days. Hyperpigmented tracts remained
Jamailpur et al. (S18)	1	Serpentine supravenuous hyperpigmentation	Docetaxel	-	7 days	Right forearm	PSE	-	-

EM: erythema multiforme; PSE: persistent serpentine supravenuous hyperpigmentation/eruption; FDE: fixed drug eruption; 5-FU: 5-fluorouracil; CHOP: cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisone; NR: not reported.

## SUPPLEMENTARY REFERENCES

- S1. Aydoğan I. Persistent serpentine supravenuous hyperpigmented eruption associated with docetaxel. *J Eur Acad Dermatol Venerol* 2005; 345-347.  
 S2. Rao R, Balachandran C. Serpentine supravenuous pigmentation. A rare vasculo-cutaneous effect induced by systemic 5-fluorouracil. *Indian J Dermatol Venerol Lepr* 2010; 76: 714-715.  
 S3. Mataix J, Bettloch I, Palmero F, Romero A. Persistent supravenuous eruption induced by intravenous bortezomib therapy. *Br J Dermatol* 2008; 158: 863-864.  
 S4. Vukelja SJ, Bonner MW, McCollough M, Cobb PW, Gaulle DA, Fanucchi PJ, et al. Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. *J Am Acad Dermatol* 1991; 25: 905-908.  
 S5. Nigro MG, Hsu S. Bleomycin-induced flagellate pigmentation. *Cutis* 2001; 68: 285-286.  
 S6. Chen G-Y, Lee JY-Y, Chen W-C. Sclerotic and retracted supravenuous hyperpigmentation associated with combination chemotherapy for metastatic breast carcinoma. *Br J Dermatol* 2005; 152: 1383-1385.  
 S7. Zimmerman GC, Keeling JH, Burris HA, Cook G, Irvin R, Kuhn J, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. *Arch Dermatol* 1995; 131: 202-206.  
 S8. Fine JD, Breathnach SM. Distinctive eruption characterized by linear supravenuous papules and erythroderma following broxuridine (bromodeoxyuridine) therapy and radiotherapy. *Arch Dermatol* 1986; 122: 199-200.  
 S9. Hirai K, Ishiko O, Nakajima S, Kanaoka Y, Nakamura Y, Oiso N, et al. Local erythematous dermatitis after intravenous docetaxel. *Gynecol Obstet Invest* 2002; 53: 118-120.  
 S10. Dorr RT, Jones SE. Inapparent infiltrations associated with vindesine administration. *Med Pediatr Oncol* 1979; 6: 285-288.  
 S11. Spencer HJ. Local erythema multiforme-like drug reaction following intravenous mitomycin C and 5-fluorouracil. *J Surg Oncol* 1984; 26: 47-50.  
 S12. Koehn HG, Balizet LB. Unusual local cutaneous reaction to dacarbazine. *Arch Dermatol* 1982; 118: 1018-1019.  
 S13. Misery L, Perrot JL, Vergnon JM, Boucheron S, Emonot A, Claudy A. Nécrolyse épidermique localisée après injection intraveineuse de vinorelbine. *Presse Med* 1992; 21: 2153.  
 S14. Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F, Polonia J. Nail changes secondary to docetaxel (Taxotere). *Dermatology* 1999; 198: 288-290.  
 S15. Suvirya S, Agrawal A, Parihar A. 5-Fluorouracil-induced bilateral persistent serpentine supravenuous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. *BMJ Case Rep* 2014; 2014: bcr2014206793.  
 S16. Das A, Kumar D, Mohanty S, Mondal A, Chowdhury S, Bandyopadhyay D. Serpentine supravenuous hyperpigmentation induced by docetaxel. *Indian J Dermatol Venerol Lepr* 2015; 81: 434.  
 S17. Akyurek FT, Sari N, Ugurluoğlu C, Kurtipek GS. Serpentine supravenuous hyperpigmentation related to carboplatin and vinorelbine chemotherapy: a case report. *Dermatol Ther* 2019; 32: e12981.  
 S18. Jamailpur I, Mogili HR, Koratala A. Serpentine supravenuous hyperpigmentation. *Clin Case Reports* 2017; 5: 1546-1547.